Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Juliet Hull

  • Home
  •  
  • Juliet Hull



  • Most Read
  • Latest Comments
  • Truscreen expands market for real time digital diagnostic testing device
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Truscreen expands market for real time digital diagnostic testing device
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Truscreen expands market for real time digital diagnostic testing device
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Truscreen expands market for real time digital diagnostic testing device
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Truscreen expands market for real time digital diagnostic testing device
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • TruScreen Secures NZ$2.35M in Fresh Capital to Expand Global Cervical Screening Footprint
    TruScreen Secures NZ$2.35M in Fresh Capital to Expand Global Cervical Screening Footprint
    • News

  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch
    CLEO meets with US FDA to develop strategy for ovarian cancer test launch
    • News

  • Genetic Signatures halts development of US respiratory product due to competition
    Genetic Signatures halts development of US respiratory product due to competition
    • News

  • Lumos completes phase 1 of developing premature birth detection test
    Lumos completes phase 1 of developing premature birth detection test
    • News

  • Genetic Technologies to pilot GeneType in US breast screening centres
    Genetic Technologies to pilot GeneType in US breast screening centres
    • News

  • Truscreen expands market for real time digital diagnostic testing device
    • News

    Truscreen expands market for real time digital diagnostic testing device

    Ahh the pap smear. The daunting, uncomfortable and downright annoying process of having a cervical swab taken to be tested for cancerous or precancerous cells, only to be repeated in 3-5 years time.  Despite being an important aspect of women’s health – COVID-19, uncomfortable gyno appointments, and misinformation means that booking in for that test

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.